Childhood, adolescent, and young adult (CAYA) cancer survivors treated with platinum-based drugs, head or brain radiotherapy, or both have an increased risk of ototoxicity (hearing loss, tinnitus, or both). To ensure optimal care and reduce consequent problems-such as speech and language, social-emotional development, and learning difficulties-for these CAYA cancer survivors, clinical practice guidelines for monitoring ototoxicity are essential. The implementation of surveillance across clinical settings is hindered by differences in definitions of hearing loss, recommendations for surveillance modalities, and remediation. To address these deficiencies, the International Guideline Harmonization Group organised an international multidisciplinary panel, including 32 experts from ten countries, to evaluate the quality of evidence for ototoxicity following platinum-based chemotherapy and head or brain radiotherapy, and formulate and harmonise ototoxicity surveillance recommendations for CAYA cancer survivors.

Children's Center for Cancer and Blood Diseases Children's Hospital Los Angeles Los Angeles CA USA; Keck School of Medicine University of Southern California Los Angeles CA USA

Department of Epidemiology and Cancer Control St Jude Children's Research Hospital Memphis TN USA

Department of Oncology St Jude Children's Research Hospital Memphis TN USA; Department of Epidemiology and Cancer Control St Jude Children's Research Hospital Memphis TN USA

Department of Otolaryngology and Head and Neck Surgery St Ann's University Hospital Brno Masaryk University Brno Czech Republic

Department of Otolaryngology Stanford University Palo Alto CA USA

Department of Pediatric and Adolescent Hematology Oncology and Children's Hematopoietic Stem Cell Transplant Unit Great North Children's Hospital and Institute of Cancer Research Newcastle University Newcastle upon Tyne UK

Department of Pediatric and Adolescent Oncology Perth Children's Hospital Nedlands WA Australia; School of Medicine University of Western Australia Perth WA Australia

Department of Pediatric Audiology Child Development and Rehabilitation Center Doernbecher Children's Hospital Oregon Health and Science University Portland OR USA

Department of Pediatrics and Adolescent Medicine Kepler Universitätsklinikum Linz Austria

Department of Pediatrics Division of Hematology Oncology The Hospital for Sick Children Toronto ON Canada

Department of Pediatrics Louisiana State University Health Sciences Center New Orleans LA USA; Division of Pediatric Hematology Oncology Children's Hospital of New Orleans New Orleans LA USA

Department of Phoniatrics and Pedaudiology University Hospital Münster Westphalian Wilhelm University of Münster Münster Germany

Departments of Radiation Oncology and Pediatrics University of Rochester Medical Center Rochester New York NY USA

Division of Pediatric Hematology Oncology Hospital for Children and Adolescents Cantonal Hospital Aarau Aarau Switzerland; Division of Pediatric Hematology Oncology University for Children's Hospital Basel Basel Switzerland; Division of Pediatric Hematology Oncology McMaster Children's Hospital McMaster University Hamilton ON Canada

Great Ormond Street Hospital for Children NHS Foundation Trust London UK

Institute for Cancer Outcomes and Survivorship Department of Pediatrics School of Medicine University of Alabama at Birmingham Birmingham Alabama AL USA

Kids Cancer Centre Sydney Children's Hospital High Street Randwick NSW Australia

Kids Cancer Centre Sydney Children's Hospital High Street Randwick NSW Australia; School of Women's and Children's Health University of New South Wales Medicine Sydney NSW Australia

Pediatric Oncology and Hematology University Hospital for Children and Adolescents Lübeck Germany

Pharmaceutical Outcomes Programme British Columbia's Children's Hospital Vancouver BC Canada; Department of Pediatrics Faculty of Medicine University of British Columbia Vancouver British Columbia Canada

Princess Máxima Center for Pediatric Oncology Utrecht Netherlands

Princess Máxima Center for Pediatric Oncology Utrecht Netherlands; Department of Pediatric Hematology and Oncology Erasmus MC Sophia Children's Hospital Rotterdam Netherlands

Princess Máxima Center for Pediatric Oncology Utrecht Netherlands; Department of Pediatric Oncology Emma Children's Hospital Amsterdam UMC University of Amsterdam Amsterdam Netherlands

Rehabilitation Services St Jude Children's Research Hospital Memphis TN USA

Rehabilitation Services St Jude Children's Research Hospital Memphis TN USA; Audiology and Speech Pathology Department British Columbia's Children's Hospital Vancouver BC Canada; School of Audiology and Speech Sciences University of British Columbia Vancouver BC Canada

Swiss Childhood Cancer Registry Institute of Social and Preventive Medicine University of Bern Bern Switzerland; Department of Pediatrics Children's University Hospital of Bern University of Bern Bern Switzerland

Swiss Childhood Cancer Registry Institute of Social and Preventive Medicine University of Bern Bern Switzerland; Institute of Epidemiology and Preventive Medicine University of Regensburg Regensburg Germany

University of Lille CHU Lille Otology and Otoneurology Lille France

Zobrazit více v PubMed

Geenen MM, Cardous-Ubbink MC, Kremer LC, et al. Medical assessment of adverse health outcomes in long-term survivors of childhood cancer. JAMA 2007; 297: 2705–15. PubMed

Gatta G, Zigon G, Capocaccia R, et al. Survival of European children and young adults with cancer diagnosed 1995–2002. Eur J Cancer 2009; 45: 992–1005. PubMed

Howlader NNA, Krapcho M, Miller D, et al. (eds). SEER Cancer Statistics Review, 1975–2013. National Cancer Institute: Bethesda, MD, 2016. http://seer.cancer.gov/csr/1975_2013 (accessed May 10, 2017).

Knight KR, Kraemer DF, Neuwelt EA. Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development. J Clin Oncol 2005; 23: 8588–96. PubMed

Bass JK, Hua CH, Huang J, et al. Hearing loss in patients who received cranial radiation therapy for childhood cancer. J Clin Oncol 2016; 34: 1248–55. PubMed PMC

Grewal S, Merchant T, Reymond R, McInerney M, Hodge C, Shearer P. Auditory late effects of childhood cancer therapy: a report from the Children’s Oncology Group. Pediatrics 2010; 125: e938–50. PubMed PMC

Clemens E, de Vries AC, Pluijm SF, et al. Determinants of ototoxicity in 451 platinum-treated Dutch survivors of childhood cancer: a DCOG late-effects study. Eur J Cancer 2016; 69: 77–85. PubMed

Landier W. Ototoxicity and cancer therapy. Cancer 2016; 122: 1647–58. PubMed

van As JW, van den Berg H, van Dalen EC. Platinum-induced hearing loss after treatment for childhood cancer. Cochrane Database Syst Rev 2016; 8: CD010181. PubMed PMC

Merchant TE, Gould CJ, Xiong X, et al. Early neuro-otologic effects of three-dimensional irradiation in children with primary brain tumors. Int J Radiat Oncol Biol Phys 2004; 58: 1194–207. PubMed

Stelmachowicz PG, Pittman AL, Hoover BM, Lewis DE, Moeller MP. The importance of high-frequency audibility in the speech and language development of children with hearing loss. Arch Otolaryngol Head Neck Surg 2004; 130: 556–62. PubMed

Davis JM, Elfenbein J, Schum R, Bentler RA. Effects of mild and moderate hearing impairments on language, educational, and psychosocial behavior of children. J Speech Hear Disord 1986; 51: 53–62. PubMed

Bess FH, Dodd-Murphy J, Parker RA. Children with minimal sensorineural hearing loss: prevalence, educational performance, and functional status. Ear Hear 1998; 19: 339–54. PubMed

Weiss A, Kuonen R, Brockmeier H, et al. Audiological monitoring in Swiss childhood cancer patients. Pediatr Blood Cancer 2018; 65: e26877. PubMed

American Speech Language Hearing Association. Guidelines for audiologic screening: childhood hearing screening. 1997. https://www.asha.org/Practice-Portal/Professional-Issues/Childhood-Hearing-Screening/ (accessed March 28, 2017).

Children’s Oncology Group. Long-term follow-up guidelines for survivors of childhood, adolescent and young adult cancers. Version 4·0–October 2013 2013. http://www.survivorshipguidelines.org/pdf/LTFUGuidelines_40.pdf (accessed March 28, 2017).

Dutch Childhood Oncology Group. Guidelines for follow-up in survivors of childhood cancer 5 years after diagnosis. 2014. https://www.skion.nl/workspace/uploads/vertaling-richtlijn-LATER-versie-final-okt-2014_2.pdf (accessed March 28, 2017).

Skinner R, Wallace WHB, Levitt GA, eds. Therapy based on long term follow up practice statement. UK Children’s Cancer Study Group Late Effects Group, 2005. http://www.uhb.nhs.uk/Downloads/pdf/CancerPbTherapyBasedLongTermFollowUp.pdf (accessed March 28, 2017).

Alberta College of Speech-Language Pathologists and Audiologists. Hearing screening guideline preschool to adult. 2015. https://acslpa.ab.ca/download/college/Hearing%20Screening%20Guideline.pdf (accessed March 31, 2017).

Australia A. Audiological Diagnostic Evaluation. 2013. https://audiology.asn.au/Tenant/C0000013/Position%20Papers/Member%20Resources/Part%20A%20Professional%20Practice%20Standards%20-%20Practice%20Operations%20July2013%20EntireDoc.pdf (accessed May 10, 2017).

Schuster S, Beck JD, Calaminus G, am Zehnhoff-Dinnesen A, Langer T. Nachsorge von krebskranken Kindern, Jugendlichen und jungen Erwachsenen - Erkennen, Vermeiden und Behandeln von Spätfolgen. 2013. https://www.awmf.org/uploads/tx_szleitlinien/025-003l_S1_Nachsorge_von_krebskranken_Kindern_Jugendlichen_06-2013-abgelaufen.pdf (accessed May 10, 2017). PubMed

Kremer LC, Mulder RL, Oeffinger KC, et al. A worldwide collaboration to harmonize guidelines for the long-term follow-up of childhood and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Pediatr Blood Cancer 2013; 60: 543–49. PubMed PMC

Clark JG. Uses and abuses of hearing loss classification. ASHA 1981; 23: 493–500. PubMed

Cochrance Childhood Cancer. 2017. http://ccg.cochrane.org (accessed May 10, 2017).

Gibbons RJ, Smith S, Antman E, American College of Cardiology, American Heart Association. American College of Cardiology/American Heart Association clinical practice guidelines: part I: where do they come from? Circulation 2003; 107: 2979–86. PubMed

Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ 2004; 328: 1490. PubMed PMC

Laverdiere C, Cheung NK, Kushner BH, et al. Long-term complications in survivors of advanced stage neuroblastoma. Pediatr Blood Cancer 2005; 45: 324–32. PubMed

Liberman PH, Goffi-Gomez MV, Schultz C, Novaes PE, Lopes LF. Audiological profile of patients treated for childhood cancer. Braz J Otorhinolaryngol 2016; 82: 623–29. PubMed PMC

Choeyprasert W, Sawangpanich R, Lertsukprasert K, et al. Cisplatin-induced ototoxicity in pediatric solid tumors: the role of glutathione S-transferases and megalin genetic polymorphisms. J Pediatr Hematol Oncol 2013; 35: e138–43. PubMed

Lewis MJ, DuBois SG, Fligor B, Li X, Goorin A, Grier HE. Ototoxicity in children treated for osteosarcoma. Pediatr Blood Cancer 2009; 52: 387–91. PubMed

Li Y, Womer RB, Silber JH. Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose. Eur J Cancer 2004; 40: 2445–51. PubMed

Peleva E, Emami N, Alzahrani M, et al. Incidence of platinum-induced ototoxicity in pediatric patients in Quebec. Pediatr Blood Cancer 2014; 61: 2012–17. PubMed

Stohr W, Langer T, Kremers A, et al. Cisplatin-induced ototoxicity in osteosarcoma patients: a report from the late effects surveillance system. Cancer Invest 2005; 23: 201–07. PubMed

Guillaume DJ, Knight K, Marquez C, Kraemer DF, Bardo DM, Neuwelt EA. Cerebrospinal fluid shunting and hearing loss in patients treated for medulloblastoma. J Neurosurg Pediatr 2012; 9: 421–27. PubMed

Frappaz D, Michon J, Hartmann O, et al. Etoposide and carboplatin in neuroblastoma: a French Society of Pediatric Oncology phase II study. J Clin Oncol 1992; 10: 1592–601. PubMed

Macdonald MR, Harrison RV, Wake M, Bliss B, Macdonald RE. Ototoxicity of carboplatin: comparing animal and clinical models at the Hospital for Sick Children. J Otolaryngol 1994; 23: 151–59. PubMed

Qaddoumi I, Bass JK, Wu J, et al. Carboplatin-associated ototoxicity in children with retinoblastoma. J Clin Oncol 2012; 30: 1034–41. PubMed PMC

Landier W, Knight K, Wong FL, et al. Ototoxicity in children with high-risk neuroblastoma: prevalence, risk factors, and concordance of grading scales—a report from the Children’s Oncology Group. J Clin Oncol 2014; 32: 527–34. PubMed PMC

Dahlborg SA, Petrillo A, Crossen JR, et al. The potential for complete and durable response in nonglial primary brain tumors in children and young adults with enhanced chemotherapy delivery. Cancer J Sci Am 1998; 4: 110–24. PubMed

Parsons SK, Neault MW, Lehmann LE, et al. Severe ototoxicity following carboplatin-containing conditioning regimen for autologous marrow transplantation for neuroblastoma. Bone Marrow Transplant 1998; 22: 669–74. PubMed

Dean JB, Hayashi SS, Albert CM, King AA, Karzon R, Hayashi RJ. Hearing loss in pediatric oncology patients receiving carboplatin-containing regimens. J Pediatr Hematol Oncol 2008; 30: 130–34. PubMed

Fouladi M, Chintagumpala M, Ashley D, et al. Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma. J Clin Oncol 2008; 26: 3749–55. PubMed PMC

Olgun Y, Aktas S, Altun Z, et al. Analysis of genetic and non genetic risk factors for cisplatin ototoxicity in pediatric patients. Int J Pediatr Otorhinolaryngol 2016; 90: 64–69. PubMed

Freyer DR, Chen L, Krailo MD, et al. Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2017; 18: 63–74. PubMed PMC

Brock PR, Maibach R, Childs M, et al. Sodium thiosulfate for protection from cisplatin-induced hearing loss. N Engl J Med 2018; 378: 2376–85. PubMed PMC

Katzenstein HM, Chang KW, Krailo M, et al. Amifostine does not prevent platinum-induced hearing loss associated with the treatment of children with hepatoblastoma: a report of the Intergroup Hepatoblastoma Study P9645 as a part of the Children’s Oncology Group. Cancer 2009; 115: 5828–35. PubMed PMC

Schoot RA, Theunissen EA, Slater O, et al. Hearing loss in survivors of childhood head and neck rhabdomyosarcoma: a long-term follow-up study. Clin Otolaryngol 2016; 41: 276–83. PubMed

Pogany L, Barr RD, Shaw A, et al. Health status in survivors of cancer in childhood and adolescence. Qual Life Res 2006; 15: 143–57. PubMed

Orgel E, Jain S, Ji L, et al. Hearing loss among survivors of childhood brain tumors treated with an irradiation-sparing approach. Pediatr Blood Cancer 2012; 58: 953–58. PubMed

Whelan K, Stratton K, Kawashima T, et al. Auditory complications in childhood cancer survivors: a report from the childhood cancer survivor study. Pediatr Blood Cancer 2011; 57: 126–34. PubMed PMC

Al-Khatib T, Cohen N, Carret AS, Daniel S. Cisplatinum ototoxicity in children, long-term follow up. Int J Pediatr Otorhinolaryngol 2010; 74: 913–19. PubMed

Bertolini P, Lassalle M, Mercier G, et al. Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss. J Pediatr Hematol Oncol 2004; 26: 649–55. PubMed

Clemens E, de Vries AC, Am Zehnhoff-Dinnesen A, et al. Hearing loss after platinum treatment is irreversible in noncranial irradiated childhood cancer survivors. Pediatr Hematol Oncol 2017; 34: 120–29. PubMed

Einarsson EJ, Petersen H, Wiebe T, et al. Long term hearing degeneration after platinum-based chemotherapy in childhood. Int J Audiol 2010; 49: 765–71. PubMed

Gurney JG, Bass JK, Onar-Thomas A, et al. Evaluation of amifostine for protection against cisplatin-induced serious hearing loss in children treated for average-risk or high-risk medulloblastoma. Neuro Oncol 2014; 16: 848–55. PubMed PMC

Hua C, Bass JK, Khan R, Kun LE, Merchant TE. Hearing loss after radiotherapy for pediatric brain tumors: effect of cochlear dose. Int J Radiat Oncol Biol Phys 2008; 72: 892–99. PubMed

Yock TI, Yeap BY, Ebb DH, et al. Long-term toxic effects of proton radiotherapy for paediatric medulloblastoma: a phase 2 single-arm study. Lancet Oncol 2016; 17: 287–98. PubMed

King AM. The national protocol for paediatric amplification in Australia. Int J Audiol 2010; 49 (suppl 1): 64–69. PubMed

American Academy of Audiology. Audiology clinical practice algorithms and statements. 2000. http://audiology-web.s3.amazonaws.com/migrated/ClinicalPracticeAlgorithms.pdf_53994824786af8.17185566.pdf (accessed March 28, 2017).

American Academy of Pediatrics, Joint Committee on Infant Hearing. Principles and guidelines for early hearing detection and intervention programs. Pediatrics 2017; 120: 897–921. PubMed

American Academy of Audiology. Audiologic guidelines for the assessment of hearing in infants and young children. 2012. https://audiology-web.s3.amazonaws.com/migrated/201208_AudGuideAssessHear_youth.pdf_5399751b249593.36017703.pdf (accessed March 28, 2017).

Canadian Agency for Drugs and Technologies in Health. Hearing screening in preschool aged children: a review of the clinical effectiveness and guidelines. 2012. https://www.cadth.ca/media/pdf/htis/nov-2012/RC0409%20PHS%20Final.pdf (accessed March 28, 2017).

Punnett A, Bliss B, Dupuis LL, Abdolell M, Doyle J, Sung L. Ototoxicity following pediatric hematopoietic stem cell transplantation: a prospective cohort study. Pediatr Blood Cancer 2004; 42: 598–603. PubMed

Abujamra AL, Escosteguy JR, Dall’Igna C, et al. The use of high-frequency audiometry increases the diagnosis of asymptomatic hearing loss in pediatric patients treated with cisplatin-based chemotherapy. Pediatr Blood Cancer 2013; 60: 474–78. PubMed

Coradini PP, Cigana L, Selistre SG, Rosito LS, Brunetto AL. Ototoxicity from cisplatin therapy in childhood cancer. J Pediatr Hematol Oncol 2007; 29: 355–60. PubMed

Dhooge I, Dhooge C, Geukens S, De Clerck B, De Vel E, Vinck BM. Distortion product otoacoustic emissions: an objective technique for the screening of hearing loss in children treated with platin derivatives. Int J Audiol 2006; 45: 337–43. PubMed

Weatherly RA, Owens JJ, Catlin FI, Mahoney DH. Cis-platinum ototoxicity in children. Laryngoscope 1991; 101: 917–24. PubMed

Einarsson EJ, Petersen H, Wiebe T, Fransson PA, Magnusson M, Moell C. Severe difficulties with word recognition in noise after platinum chemotherapy in childhood, and improvements with open-fitting hearing-aids. Int J Audiol 2011; 50: 642–51. PubMed

Kuthubutheen J, Hedne CN, Krishnaswamy J, Rajan GP. A case series of paediatric hearing preservation cochlear implantation: a new treatment modality for children with drug-induced or congenital partial deafness. Audiol Neurootol 2012; 17: 321–30. PubMed

Stachler RJ, Chandrasekhar SS, Archer SM, et al. Clinical practice guideline: sudden hearing loss. Otolaryngol Head Neck Surg 2012; 146: S1–35. PubMed

National Institute for Health and Care Excellence. Cochlear implants for children and adults with severe to profound deafness. NICE: London, 2009. https://www.nice.org.uk/guidance/ta166 (accessed March 28, 2017).

New York state Department of Health. Clinical Practice Guideline: report of the recommendations. Hearing loss: assessment and intervention for young children (age 0–3 years). 2007. https://www.health.ny.gov/community/infants_children/early_intervention/docs/guidelines_hearing_loss_recommendations.pdf (accessed March 28, 2017).

American Association of Audiology. Clinical Practice Guidelines on pediatric amplification. 2013. http://galster.net/wp-content/uploads/2013/07/AAA-2013-Pediatric-Amp-Guidelines.pdf (accessed March 28, 2017).

Tunkel DE, Bauer CA, Sun GH, et al. Clinical practice guideline: tinnitus. Otolaryngol Head Neck Surg 2014; 151: S1–40. PubMed

van As JW, van den Berg H, van Dalen EC. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer. Cochrane Database Syst Rev 2016; 9: CD009219. PubMed PMC

Truong MT, Winzelberg J, Chang KW. Recovery from cisplatin-induced ototoxicity: a case report and review. Int J Pediatr Otorhinolaryngol 2007; 71: 1631–38. PubMed

Williams D Does irrigation of the ear to remove impacted wax improve hearing? Br J Community Nurs 2005; 10: 228–32. PubMed

American College of Radiology. Appropriateness criteria: hearing loss and/or vertigo. 1996. https://www.dcamedical.com/pdf/appropriateness-criteria-vertigo-and-hearing-loss.pdf (accessed March 28, 2017).

National Institute for Health and Care Excellence. Auditory brainstem implants for children and adults with severe to profound deafness. NICE: London, 2005. https://www.nice.org.uk/guidance/ipg108 (accessed March 28, 2017).

Audiology Australia. Professional practice standards: audiological rehabilitation. 2013. https://audiology.asn.au/Tenant/C0000013/Position%20Papers/Member%20Resources/Clinical%20Standards%20partb%20-%20whole%20document%20July13%201.pdf (accessed March 28, 2017).

Kushner BH, Budnick A, Kramer K, Modak S, Cheung NK. Ototoxicity from high-dose use of platinum compounds in patients with neuroblastoma. Cancer 2006; 107: 417–22. PubMed

Moore DR. Auditory development and the role of experience. Br Med Bull 2002; 63: 171–81. PubMed

Panova MV, Geneva IE, Madjarova KI, Bosheva MN. Hearing loss in patients with shunt-treated hydrocephalus. Folia Med (Plovdiv) 2015; 57: 216–22. PubMed

van Veelen-Vincent ML, Delwel EJ, Teeuw R, et al. Analysis of hearing loss after shunt placement in patients with normal-pressure hydrocephalus. J Neurosurg 2001; 95: 432–34. PubMed

Walsted A, Nielsen OA, Borum P. Hearing loss after neurosurgery. The influence of low cerebrospinal fluid pressure. J Laryngol Otol 1994; 108: 637–41. PubMed

Stoeckli SJ, Bohmer A. Persistent bilateral hearing loss after shunt placement for hydrocephalus. Case report. J Neurosurg 1999; 90: 773–75. PubMed

Miyazaki Y, Tomii M, Sawauchi S, Ikeuchi S, Yuki K, Abe T. [A case of hearing loss caused by overdrainage of cerebrospinal fluid after ventriculo-peritoneal shunting procedure]. No Shinkei Geka 1997; 25: 367–71. PubMed

Lopponen H, Sorri M, Serlo W, von Wendt L. Audiological findings of shunt-treated hydrocephalus in children. Int J Pediatr Otorhinolaryngol 1989; 18: 21–30. PubMed

Bass JK, Huang J, Onar-Thomas A, et al. Concordance between the chang and the International Society of Pediatric Oncology (SIOP) ototoxicity grading scales in patients treated with cisplatin for medulloblastoma. Pediatr Blood Cancer 2014; 61: 601–05. PubMed PMC

Brock PR, Knight KR, Freyer DR, et al. Platinum-induced ototoxicity in children: a consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston ototoxicity scale. J Clin Oncol 2012; 30: 2408–17. PubMed PMC

Auditory complications among childhood cancer survivors and health-related quality of life: a PanCareLIFE study

Tailoring neoadjuvant chemotherapy for a pregnant patient diagnosed with IB2 squamous cervical carcinoma

Evaluating the feasibility, effectiveness and costs of implementing person-centred follow-up care for childhood cancer survivors in four European countries: the PanCareFollowUp Care prospective cohort study protocol

TCERG1L allelic variation is associated with cisplatin-induced hearing loss in childhood cancer, a PanCareLIFE study

Guidance regarding COVID-19 for survivors of childhood, adolescent, and young adult cancer: A statement from the International Late Effects of Childhood Cancer Guideline Harmonization Group